Status:

COMPLETED

Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Lead Sponsor:

Novartis

Conditions:

Metabolic Syndrome

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

Other effects of fluvastatin are investigated in German patients with metabolic syndrome.

Eligibility Criteria

Inclusion

  • Written informed consent
  • Male and female patients, aged between 18 and 75 years
  • Metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII)

Exclusion

  • History of heart failure
  • HIV positive
  • Stroke
  • Other protocol defined inclusion and exclusion criteria may apply.

Key Trial Info

Start Date :

October 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2006

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT00138528

Start Date

October 1 2004

End Date

February 1 2006

Last Update

February 23 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novartis

Nuremberg, Germany